Amgen (AMGN) Operating Margin (2009 - 2026)
Amgen (AMGN) posted quarterly Operating Margin of 30.94% for Q1 2026, up 1648.0% year-over-year from 1.77% in Q1 2025, and up 12.21% on a QoQ basis from 27.57% in Q4 2025.
Amgen (AMGN) Operating Margin (2009 - 2026) Analysis & Trends
Amgen (AMGN) has reported Operating Margin for 18 consecutive years, with 30.94% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 1648.0% year-over-year to 30.94%; the TTM figure through Mar 2026 stood at 28.39% (up 658.0% YoY), while the FY2025 annual figure was 24.71%, up 299.0% from the prior year.
- Operating Margin came in at 30.94% for Q1 2026 at Amgen, up from 27.57% in the prior quarter.
- The five-year high for Operating Margin was 485.84% in Q4 2022, with the low at 13.31% in Q1 2024.
- Average Operating Margin over 5 years is 54.56%, with a median of 28.94% recorded in 2025.
- Across the five-year window, Operating Margin surged 45218 bps in 2022 and sank 47033 bps in 2023, its largest moves.
- Year by year, Operating Margin stood at 485.84% in 2022, then sank by 97 bps to 15.51% in 2023, then surged by 64 bps to 25.43% in 2024, then gained by 8 bps to 27.57% in 2025, then rose by 12 bps to 30.94% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 30.94%, 27.57%, and 26.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 47.98% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 26.44% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 26.60% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.51% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -286.83% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.94% |
| Dec 31, 2025 | 27.57% |
| Sep 30, 2025 | 26.43% |
| Jun 30, 2025 | 28.94% |
| Mar 31, 2025 | 14.46% |
| Dec 31, 2024 | 25.43% |
| Sep 30, 2024 | 24.07% |
| Jun 30, 2024 | 22.76% |
| Mar 31, 2024 | 13.31% |
| Dec 31, 2023 | 15.51% |
| Sep 30, 2023 | 29.28% |
| Jun 30, 2023 | 38.42% |
| Mar 31, 2023 | 31.47% |
| Dec 31, 2022 | 485.84% |
| Sep 30, 2022 | 39.99% |
| Jun 30, 2022 | 33.00% |
| Mar 31, 2022 | 40.08% |
| Dec 31, 2021 | 33.65% |
| Sep 30, 2021 | 35.46% |
| Jun 30, 2021 | 12.69% |